[go: up one dir, main page]

MX2009009581A - Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta. - Google Patents

Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.

Info

Publication number
MX2009009581A
MX2009009581A MX2009009581A MX2009009581A MX2009009581A MX 2009009581 A MX2009009581 A MX 2009009581A MX 2009009581 A MX2009009581 A MX 2009009581A MX 2009009581 A MX2009009581 A MX 2009009581A MX 2009009581 A MX2009009581 A MX 2009009581A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
indazoles
receptor beta
mediated disorders
beta mediated
Prior art date
Application number
MX2009009581A
Other languages
English (en)
Inventor
Xi Liang
David Timothy Macpherson
Steven James Stanway
Andrew Kenneth Takle
Christopher Norbert Johnson
David G Jones
Aaron B Miller
Antoinette Naylor
Giancarlo Trani
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2009009581A publication Critical patent/MX2009009581A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a derivados de indazol novedosos (I) que tienen actividad farmacológica, procedimientos para su preparación, composiciones que los contienen, y usos de estos compuestos en el tratamiento de enfermedades mediadas por el receptor de estrógenos beta. (ver fórmula).
MX2009009581A 2007-03-07 2008-03-05 Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta. MX2009009581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0704407.6A GB0704407D0 (en) 2007-03-07 2007-03-07 Compounds
PCT/EP2008/052664 WO2008107455A1 (en) 2007-03-07 2008-03-05 Indazoles used to treat estrogen receptor beta mediated disorders

Publications (1)

Publication Number Publication Date
MX2009009581A true MX2009009581A (es) 2009-09-16

Family

ID=37988543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009581A MX2009009581A (es) 2007-03-07 2008-03-05 Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.

Country Status (16)

Country Link
US (1) US7960563B2 (es)
EP (1) EP2118068A1 (es)
JP (1) JP2010520259A (es)
KR (1) KR20090118998A (es)
CN (1) CN101679288A (es)
AR (1) AR065605A1 (es)
AU (1) AU2008223850A1 (es)
BR (1) BRPI0808464A2 (es)
CA (1) CA2680109A1 (es)
CL (1) CL2008000647A1 (es)
EA (1) EA200970835A1 (es)
GB (1) GB0704407D0 (es)
MX (1) MX2009009581A (es)
PE (1) PE20081878A1 (es)
TW (1) TW200848025A (es)
WO (1) WO2008107455A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
NZ584148A (en) 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
GB0803017D0 (en) 2008-02-19 2008-03-26 Glaxo Group Ltd Compounds
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2828243B1 (en) 2012-03-20 2018-10-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
WO2019226936A1 (en) * 2018-05-23 2019-11-28 The Board Of Trustees Of The University Of Illinois Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (ms) and other demyelinating, inflammatory and neurodegenerative diseases
CN110483403A (zh) * 2019-09-02 2019-11-22 南通大学 一种5-溴-4-甲氧基-1h-吲唑的合成方法
EP4069212A4 (en) * 2019-12-04 2024-03-06 Arcus Biosciences, Inc. HIF-2 ALPHA INHIBITORS
KR20220155593A (ko) 2020-03-19 2022-11-23 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018008A1 (en) * 1992-03-09 1993-09-16 Zeneca Limited Novel arylindazoles and their use as herbicides
DE4236105A1 (de) 1992-10-26 1994-04-28 Hoechst Ag Arylboronsäuren als Vorprodukte zur Herstellung von Komponenten von Flüssigkristallmischungen
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JPH0770078A (ja) * 1993-07-08 1995-03-14 Fuji Photo Film Co Ltd インダゾールの製造方法
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
BR9607035A (pt) 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
EP0935000A3 (en) 1995-09-08 1999-09-08 Karo Bio Ab Orphan receptor
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
IL125849A (en) 1996-04-12 2003-10-31 Searle & Co Substituted benzenesulfonamide derivatives, their preparation and pharmaceutical compositions comprising them
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE317845T1 (de) 1997-09-05 2006-03-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6407261B1 (en) * 1998-04-17 2002-06-18 Eli Lilly And Company Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
ES2228127T3 (es) 1998-11-03 2005-04-01 Glaxo Group Limited Derivados de pirazolopiridina como inhibidores selectivos de cox-2.
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
AU2004257966B2 (en) 2003-06-27 2008-10-02 Asahi Kasei Kabushiki Kaisha Cell diffrentiation inhibitor, cell culture method using the same, liquid culture medium and cultured cell line
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CN101679288A (zh) 2010-03-24
GB0704407D0 (en) 2007-04-18
US7960563B2 (en) 2011-06-14
CA2680109A1 (en) 2008-09-12
AU2008223850A1 (en) 2008-09-12
PE20081878A1 (es) 2009-03-05
TW200848025A (en) 2008-12-16
WO2008107455A1 (en) 2008-09-12
KR20090118998A (ko) 2009-11-18
CL2008000647A1 (es) 2009-01-02
JP2010520259A (ja) 2010-06-10
EP2118068A1 (en) 2009-11-18
EA200970835A1 (ru) 2010-04-30
US20100087502A1 (en) 2010-04-08
BRPI0808464A2 (pt) 2014-07-15
AR065605A1 (es) 2009-06-17

Similar Documents

Publication Publication Date Title
MX2009009581A (es) Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
PL1979355T3 (pl) Pochodne spiro imidazoli jako modulatory PPAR
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
IL193479A0 (en) Modulators of muscarinic receptors
MY156822A (en) Indole derivatives as s1p1 receptor agonists
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MX2011008972A (es) Derivados de pirazol usados como antagonistas del receptor ccr4.
JO2645B1 (en) Vehicles
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
EP2004188A4 (en) BENZOIMIDAZOLE-2-YL PYRIDINES AS HISTAMINE H4 RECEPTOR MODULATORS
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
MX2009009153A (es) Pirano-pirazol-aminas.
MX2010009462A (es) Derivados de indazol.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
GEP20146103B (en) Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).